Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK₂ receptor antagonist

References

• GRindi, DSKlimstra, RArnold, CCapella, DSKlimstra, GKloppel, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: FTBosman, FCarneiro, RHHruban, ND Theise, editors. WHO Classification of Tumors of the Digestive System, 4th ed. Lyon: IARC Pr, 2010: 13–14.
   Google Scholar
• GKlöppel. Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 2011;18:S1–16.
   PubMed Web of Science ®Google Scholar
• FNoble, SAWank, JNCrawley, JBradwejn, KBSeroogy, MHamon, et al. International Union of Pharmacology. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev 1999;51:745–81.
   PubMed Web of Science ®Google Scholar
• GJDockray, AVarro, RDimaline, TWang. The gastrins: their production and biological activities. Annu Rev Physiol 2001;63:119–39.
   PubMed Web of Science ®Google Scholar
• RDimaline, AVarro. Attack and defence in the gastric epithelium - a delicate balance. Exp Physiol 2007;92:591–601.
   PubMedGoogle Scholar
• AVarro, JEArdill. Gastrin: an analytical review. Ann Clin Biochem 2003;40:472–80.
   PubMed Web of Science ®Google Scholar
• KGNørsett, ISteele, CDuval, SJSammut, SVMurugesan, SKenny, et al. Gastrin stimulates expression of plasminogen activator inhibitor-1 in gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol 2011;301:G446–53.
   Google Scholar
• SKenny, CDuval, SJSammut, ISteele, DMPritchard, JCAtherton, et al. Increased expression of the urokinase plasminogen activator system by Helicobacter pylori in gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol 2008;295:G431–41.
   PubMed Web of Science ®Google Scholar
• AVarro, SKenny, EHemers, CMcCaig, SPrzemeck, TCWang, et al. Increased gastric expression of MMP-7 in hypergastrinemia and significance for epithelial-mesenchymal signaling. Am J Physiol Gastrointest Liver Physiol 2007;292:G1133–40.
   Google Scholar
• SAlmeida-Vega, KCatlow, SKenny, RDimaline, AVarro. Gastrin activates paracrine networks leading to induction of PAI-2 via MAZ and ASC-1. Am J Physiol Gastrointest Liver Physiol 2009;296:G414–23.
   Google Scholar
• ZEKhan, TCWang, GCui, ALChi, RDimaline. Transcriptional regulation of the human trefoil factor, TFF1, by gastrin. Gastroenterology 2003;125:510–21.
   PubMedGoogle Scholar
• STu, ALChi, SLim, GCui, ZDubeykovskaya, WAi, et al. Gastrin regulates the TFF2 promoter through gastrin-responsive cis-acting elements and multiple signaling pathways. Am J Physiol Gastrointest Liver Physiol 2007;292:G1726–37.
   Google Scholar
• SAWatson, AMGrabowska, MEl-Zaatari, ATakhar. Gastrin - active participant or bystander in gastric carcinogenesis? Nat Rev Cancer 2006;6:936–46.
   PubMed Web of Science ®Google Scholar
• GCui, STakaishi, WAi, GCui, ZDubeykovskaya, WAi, et al. Gastrin-induced apoptosis contributes to carcinogenesis in the stomach. Lab Invest 2006;86:1037–51.
   PubMedGoogle Scholar
• GRindi, OLuinetti, MCornaggia, CCapella, ESolcia. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993;104:994–1006.
   PubMed Web of Science ®Google Scholar
• MDBurkitt, DMPritchard. Pathogenesis and management of gastric carcinoid tumours. Aliment Pharmacol Ther 2006;24:1305–20.
   PubMed Web of Science ®Google Scholar
• WLNeumann, ECoss, MRugge, RMGenta. Autoimmune atrophic gastritis -pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol 2013;10:529–41.
   PubMed Web of Science ®Google Scholar
• BAnnibale, ELahner, GDFave. Diagnosis and management of pernicious anemia. Curr Gastroenterol Rep 2011;13:518–24.
   PubMedGoogle Scholar
• LVannella, ELahner, BAnnibale. Risk for gastric neoplasias in patients with chronic atrophic gastritis: a critical reappraisal. World J Gastroenterol 2012;18:1279–85.
   PubMed Web of Science ®Google Scholar
• MMD’Elios, BJAppelmelk, AAmedei, MPBergman, GDel Prete. Gastric autoimmunity: the role of Helicobacter pylori and molecular mimicry. Trends Mol Med 2004;10:316–23.
   PubMed Web of Science ®Google Scholar
• ØSørdal, HWaldum, ISNordrum, MBoyce, KBergh, BMunkvold, et al. The gastrin receptor antagonist netazepide (YF476) prevents oxyntic mucosal inflammation induced by Helicobacter pylori infection in Mongolian gerbils. Helicobacter 2013;18:397–405.
   PubMedGoogle Scholar
• TIto, HIgarashi, RTJensen. Zollinger-Ellison syndrome: recent advances and controversies. Curr Opin Gastroenterol 2013;29:650–61.
   PubMed Web of Science ®Google Scholar
• MBerna, BAnnibale, MMarignani, TVinn Leung, VCorieto, APace, et al. A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison Syndrome: identification of risk factors. J Clin Endocrinol Metab 2008;93:1582–91.
   PubMed Web of Science ®Google Scholar
• RFossmark, GQvigstad, HLWaldum. Gastric cancer: animal studies on the risk of hypoacidity and hypergastrinaemia. World J Gastroenterol 2008;14:1646–51.
   PubMed Web of Science ®Google Scholar
• GQvigstad, SFalkmer, BWestre, HLWaldum. Clinical and histopathological tumour progression in ECL cell carcinoids. APMIS 1999;107:1085–92.
   PubMed Web of Science ®Google Scholar
• BIHirschowitz, JGriffith, DPellegrin, OWCummings. Rapid regression of enterochromaffinlike cell gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology 1992;102:1409–18.
   PubMed Web of Science ®Google Scholar
• RHerranz. Cholecystokinin antagonists: pharmacological and therapeutic potential. Med Res Rev 2003;23:559–605.
   PubMed Web of Science ®Google Scholar
• JWBlack, SBKalindjian. Gastrin agonists and antagonists. Pharmacol Toxicol 2002;91:275–81.
   PubMedGoogle Scholar
• GSemple, HRyder, DPRooker, ARBatt, DAKendrick, MSzelke, et al. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N’-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist. J Med Chem 1997;40:331–41.
   PubMed Web of Science ®Google Scholar
• YTakinami, HYuki, ANishida, SAkuzawa, AUchida, YTakemoto, et al. YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo. Aliment Pharmacol Ther 1997;11:113–20.
   PubMed Web of Science ®Google Scholar
• YTakemoto, HYuki, ANishida, HIto, AKobayashi-Uchida, YTakinami, et al. Effects of YF476, a potent and selective gastrin/cholecystokinin-B receptor antagonist, on gastric acid secretion in beagle dogs with gastric fistula. Arzneimittelforschung 1998;48:403–7.
   PubMedGoogle Scholar
• TKonagaya, MBernsand, PNorlén, RHåkanson. Mobilization of rat stomach ECL-cell histamine in response to short- or long-term treatment with omeprazole and/or YF 476 studied by gastric submucosal microdialysis in conscious rats. Br J Pharmacol 2001;133:37–42.
   PubMedGoogle Scholar
• DChen, CMZhao, PNorlén, MBjörkqvist, XQDing, MKitano, et al. Effect of cholecystokinin-2 receptor blockade on rat stomach ECL cells. A histochemical, electron-microscopic and chemical study. Cell Tissue Res 2000;299:81–95.
   PubMedGoogle Scholar
• TCMartinsen, SKawase, RHåkanson, SHTorp, RFossmark, GQvigstad, et al. Spontaneous ECL cell carcinomas in cotton rats: natural course and prevention by a gastrin receptor antagonist. Carcinogenesis 2003;24:1887–96.
   PubMed Web of Science ®Google Scholar
• MKidd, ZLSiddique, IDrozdov, BIGustafsson, RLCamp, JWBlack, et al. The CCK(2) receptor antagonist, YF476, inhibits mastomys ECL cell hyperplasia and gastric carcinoid tumor development. Regul Pept 2010;162:52–60.
   PubMedGoogle Scholar
• MBoyce, ODavid, KDarwin, TMitchell, AJohnston, SWarrington. Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects. Aliment Pharmacol Ther 2012;36:181–9.
   PubMedGoogle Scholar
• MBoyce, SWarrington. Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24-h gastric acidity and gastrin in healthy subjects. Br J Clin Pharmacol 2013;76:680–8.
   PubMedGoogle Scholar
• MBoyce, SWarrington, JBlack. Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects. Br J Clin Pharmacol 2013;76:689–98.
   PubMedGoogle Scholar
• MBoyce, SDowen, GTurnbull, Fvan den Berg, CMZhao, DChen, et al. Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia: a double-blind trial in healthy subjects. Br J Clin Pharmacol 2014. 10.1111/bcp.12534 [Epub ahead of print].
   PubMedGoogle Scholar
• Recommendation on elements required to support the medical plausibility and the assumption of significant benefit for an orphan designation EMA/COMP/15893/2009. In COMP, editor. London, UK: European Medicines Agency; 2010.
   Google Scholar
• European Commission Enterprise Directorate-General. Guideline on the Format and Content of Applications for Designation as Orphan Medicinal Products and on the Transfer of Designations from One Sponsor to Another (ENTR/6283/00 Rev 3), Brussels: European Commission; 2007.
   Google Scholar
• Part 316 – Orphan Drugs: USA Food and Drug Administration, 2013.
   Google Scholar
• Pharmaceutical Administration and Regulations in Japan. Section 4.5, page 41. Available from http://www.jpma.or.jp/english/parj/1003.html.
   Google Scholar
• European Network of Cancer Registries. Available from http://www.encr.eu/index.php/who-we-are/membership.ecr. Accessed July 2007.
   Google Scholar
• Factbook geos ee. Available from https://www.cia.gov/library/publications/the-world-factbook/index.html. Accessed 11 August 2014.
   Google Scholar
• IMModlin, KDLye, MKidd. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 2004;99:23–32.
   PubMed Web of Science ®Google Scholar
• Health UNIo. Surveillance, Epidemiology and End Results (SEER). Available from http://seer.cancer.gov.
   Google Scholar
• Census population estimates. Available from http://www.census.gov/popest/. Accessed 11 August 2014.
   Google Scholar
• Statistics hub. Available from http://www.statistics.gov.uk/hub/population/index.html. Accessed 11 August 2014.
   Google Scholar
• TIto, MTanaka, HSasano, YOsamura, ISasaki, WKimura, Neuroendocrine Tumor Workshop of Japan. Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors. J Gastroenterol 2007;42:497–500.
   PubMed Web of Science ®Google Scholar
• TIto, HSasano, MTanaka, RYOsamura, ISasaki, WKimura, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 2010;45:234–43.
   PubMed Web of Science ®Google Scholar
• OHauso, BIGustafsson, MKidd, HLWaldum, IDrozdov, AKChan, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer 2008;113:2655–64.
   PubMed Web of Science ®Google Scholar
• MBNiederle, MHackl, KKaserer, BNiederle. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer 2010;17:909–18.
   PubMed Web of Science ®Google Scholar
• NHodgson, LGKoniaris, ASLivingstone, DFranceschi. Gastric carcinoids: a temporal increase with proton pump introduction. Surg Endosc 2005;19:1610–12.
   PubMedGoogle Scholar
• JCYao, MHassan, APhan, CDagohoy, CLeary, JEMares, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063–72.
   PubMed Web of Science ®Google Scholar
• EScott. Prevalence of pernicious anaemia in Great Britain. J Coll Gen Pract 1960;3:80–4.
   PubMedGoogle Scholar
• ABPedersen, JMosbech. Morbidity of pernicious anaemia. Incidence, prevalence, and treatment in a Danish county. Acta Med Scand 1969;185:449–52.
   PubMedGoogle Scholar
• RCarmel. Prevalence of undiagnosed pernicious anemia in the elderly. Arch Intern Med 1996;156:1097–100.
   PubMedGoogle Scholar
• KBorch. Epidemiologic, clinicopathologic, and economic aspects of gastroscopic screening of patients with pernicious anemia. Scand J Gastroenterol 1986;21:21–30.
   PubMed Web of Science ®Google Scholar
• AKokkola, SMSjoblom, RHaapiainen, PSipponen, PPuolakkainen, HJärvinen, et al. The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia. A prospective follow-up study. Scand J Gastroenterol 1998;33:88–92.
   PubMed Web of Science ®Google Scholar
• SMSjoblom, PSipponen, HJarvinen. Gastroscopic follow up of pernicious anaemia patients. Gut 1993;34:28–32.
   PubMed Web of Science ®Google Scholar
• FPotet, CFlorent, EBenhamou, FCabrières, GBommelaer, JHostein, et al. Chronic gastritis: prevalence in the French population. Gastroenterol Clin Biol 1993;17:103–8.
   PubMedGoogle Scholar
• ELahner, BAnnibale. Pernicious anemia: new insights from a gastroenterological point of view. World J Gastroenterol 2009;15:5121–8.
   PubMed Web of Science ®Google Scholar
• JSoga. Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported cases. Cancer 2005;103:1587–95.
   PubMed Web of Science ®Google Scholar
• JSoga. Carcinoid tumours: a statistical analysis of a Japanese series of 3,126 reported and 1,180 autopsy cases. Acta Med Biol 1994;42:87–102.
   Google Scholar
• JSoga. Gastric carcinoids: a statistical evaluation of 1,094 cases collected from the literature. Surg Today 1997;27:892–901.
   PubMedGoogle Scholar
• LEllis, MJShale, MPColeman. Carcinoid tumors of the gastrointestinal tract: trends in incidence in England since 1971. Am J Gastroenterol 2010;105:2563–9.
   PubMed Web of Science ®Google Scholar
• LVannella, ASbrozzi-Vanni, ELahner, CBordi, EPilozzi, VDCorleto, et al. Development of type I gastric carcinoid in patients with chronic atrophic gastritis. Aliment Pharmacol Ther 2011;33:1361–9.
   PubMed Web of Science ®Google Scholar
• Designation EU/3/07/451. Register of designated Orphan Medicinal Products. Available from http://ec.europa.eu/health/documents/community-register/html/orphreg.htm. Accessed 11 August 2014.
   Google Scholar
• Designation 07-2432. Orphan Drug Product designation database. Available from http://www.accessdata.fda.gov/scripts/opdlisting/oopd/. Accessed 11 August 2014.
   Google Scholar
• SMassironi, VSciola, MPSpampatti, MPeracchi, DConte. Gastric carcinoids: between underestimation and overtreatment. World J Gastroenterol 2009;15:2177–83.
   PubMed Web of Science ®Google Scholar
• JBJansen, ECKlinkenberg-Knol, SGMeuwissen, SGMeuwissen, JWDe Bruijne, HPFesten, et al. Effect of long-term treatment with omeprazole on serum gastrin and serum group A and C pepsinogens in patients with reflux esophagitis. Gastroenterology 1990;99:621–8.
   PubMed Web of Science ®Google Scholar
• GRindi, RFiocca, AMorocutti, AJacobs, NMiller, BThjodleifsson, et al. Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. Eur J Gastroenterol Hepatol 2005;17:559–66.
   PubMed Web of Science ®Google Scholar
• GBrunner, CAthmann, ASchneider. Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment Pharmacol Ther 2012;36:37–47.
   PubMed Web of Science ®Google Scholar
• LLaine, DAhnen, CMcClain, ESolcia, JHWalsh. Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000;14:651–68.
   PubMed Web of Science ®Google Scholar
• RTJensen. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol 2006;98:4–19.
   PubMed Web of Science ®Google Scholar
• HLWaldum, EBrenna, AKSandvik. Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections. Expert Opin Drug Saf 2002;1:29–38.
   PubMedGoogle Scholar
• CSJianu, OJLange, TViset, GQvigstad, TCMartinsen, RFougner, et al. Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scand J Gastroenterol 2012;47:64–7.
   PubMed Web of Science ®Google Scholar
• CSJianu, RFossmark, TViset, GQvigstad, OSørdal, RMårvik, et al. Gastric carcinoids after long-term use of a proton pump inhibitor. Aliment Pharmacol Ther 2012;36:644–9.
   PubMed Web of Science ®Google Scholar
• LVannella, ELahner, JOsborn, BAnnibale. Systematic review: gastric cancer incidence in pernicious anaemia. Aliment Pharmacol Ther 2013;37:375–82.
   PubMed Web of Science ®Google Scholar
• JSoga, YYakuwa. The gastrinoma/Zollinger-Ellison syndrome: statistical evaluation of a Japanese series of 359 cases. J Hepatobiliary Pancreat Surg 1998;5:77–85.
   PubMedGoogle Scholar
• IModlin, KLye, MKidd. Carcinoid tumors of the stomach. Surg Oncol 2001;12:153–72.
   Google Scholar
• YSato, MIwafuchi, JUeki, AYoshimura, TMochizuki, HMotoyama, et al. Gastric carcinoid tumors without autoimmune gastritis in Japan: a relationship with Helicobacter pylori infection. Dig Dis Sci 2002;47:579–85.
   PubMed Web of Science ®Google Scholar
• UPlockinger, GRindi, RArnold, BEriksson, EPKrenning, WWde Herder, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004;80:394–424.
   PubMed Web of Science ®Google Scholar
• RSalazar, BWiedenmann, GRindi, PRuszniewski. ENETS 2011 consensus guidelines for the management of patients with digestive neuroendocrine tumors: an update. Neuroendocrinology 2012;95:71–3.
   PubMed Web of Science ®Google Scholar
• MHKulke, LBAnthony, DLBushnell, WWde Herder, SJGoldsmith, DSKlimstra, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010;39:735–52.
   PubMed Web of Science ®Google Scholar
• EMerola, ASbrozzi-Vanni, FPanzuto, GD’Ambra, EDi Giulio, EPilozzi, et al. Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology 2012;95:207–13.
   PubMed Web of Science ®Google Scholar
• IMModlin, MPavel, MKidd, BIGustafsson. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010;31:169–88.
   PubMed Web of Science ®Google Scholar
• GFDakin, RRWarner, APomp, BSalky, WBInabnet. Presentation, treatment, and outcome of type 1 gastric carcinoid tumors. J Surg Oncol 2006;93:368–72.
   PubMed Web of Science ®Google Scholar
• JOzao-Choy, KBuch, JAStrauchen, RRWarner, CMDivino. Laparoscopic antrectomy for the treatment of type I gastric carcinoid tumors. J Surg Res 2010;162:22–5.
   PubMed Web of Science ®Google Scholar
• RFossmark, ØSørdal, CSJianu, GQvigstad, ISNordrum, MBoyce, et al. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment Pharmacol Ther 2012;36:1067–75.
   PubMed Web of Science ®Google Scholar
• ARMoore, MBoyce, IASteele, FCampbell, AVarro, DMPritchard. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis. PLoS One 2013;8:e76462.
   PubMed Web of Science ®Google Scholar